Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 64.2% in May

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 50,300 shares, a decline of 64.2% from the April 30th total of 140,500 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 46,000 shares, the short-interest ratio is presently 1.1 days.

Entera Bio Stock Performance

Shares of NASDAQ ENTX traded up $0.02 during midday trading on Friday, reaching $1.84. 20,034 shares of the company traded hands, compared to its average volume of 70,562. The firm has a market cap of $83.40 million, a PE ratio of -7.06 and a beta of 1.51. The stock's 50-day simple moving average is $1.93 and its 200-day simple moving average is $2.05. Entera Bio has a 12 month low of $1.41 and a 12 month high of $2.79.

Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $0.04 million for the quarter. On average, equities research analysts expect that Entera Bio will post -0.28 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Entera Bio in a report on Tuesday, March 18th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Perigon Wealth Management LLC bought a new position in shares of Entera Bio during the fourth quarter valued at $325,000. Northern Trust Corp bought a new position in shares of Entera Bio in the fourth quarter valued at about $450,000. Knoll Capital Management LLC raised its holdings in shares of Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after buying an additional 2,000,000 shares during the last quarter. Parkman Healthcare Partners LLC raised its holdings in shares of Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after buying an additional 25,900 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after buying an additional 6,310 shares during the last quarter. 14.11% of the stock is owned by institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.